Galderma relaunched Sculptra, an injectable poly-L-lactic acid, in Europe, after analyzing new data. Sculptra is a collagen stimulator that provides structure and support to the skin, as with facial aging the skin’s natural collagen supply may decrease and could lead to skin laxity, wrinkles, and roughness.
The product can now be used right after a two-minute reconstitution and has increased levels of comfort for patients. Before, healthcare professionals would have to wait two hours after reconstitution to use the product. Now, Sculptra has the fastest reconstitution protocol of any injectable poly-L-lactic acid (PLLA) available in Europe. The updated usage comes from new data from physiochemical studies, and results from a randomized, evaluator-blinded, parallel-group, multi-center study evaluating the safety and effectiveness of two different dilutions of Sculptra. The study found using the product right after reconstitution caused less pain on injection and was well-tolerated. “We are delighted to bring this expanded Sculptra offering to healthcare professionals in Europe, and yesterday’s launch event was an exciting, well-attended re-introduction to Sculptra and Galderma’s larger aesthetics portfolio,” says Alexandre Brennan, global business unit head of aesthetics at Galderma. “We continue to build a unique and extensive aesthetics offering at Galderma, and are proud to relaunch Sculptra in Europe as the foundation of our portfolio alongside a range of complementary treatments to deliver impressive and long-lasting results for healthcare professionals and their patients.”